TM
RPRX icon

Taproot Management’s Royalty Pharma RPRX Stock Holding History

Taproot Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-129,592
Closed -$6.22M – 139
2026
Q1 		$6.22M Sell
129,592
-155,095
-54% -$6.79M 1.17% 16
2025
Q4 		$11M Buy
+284,687
New +$10.9M 1.78% 10

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Taproot Management's RPRX Position: Q2 2026 in Review

Taproot Management sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 129,592 shares — an estimated $6.22M sold.

Taproot Management first reported a position in RPRX in Q4 2025 and held it in 2 quarters. The position peaked at $11M in Q4 2025. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Taproot Management reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
  • Taproot Management sold 129,592 Royalty Pharma shares in Q2 2026, an estimated $6.22M.
  • Taproot Management first reported a position in Royalty Pharma in Q4 2025 and held it in 2 quarters.
  • Taproot Management's Royalty Pharma position peaked at $11M in Q4 2025.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Taproot Management's 13F filing for Q2 2026.